Switching to Skyrizi (risankizumab-rzaa) alone could be a viable option for managing your psoriatic arthritis (PsA) and psoriasis. Here are some key points about Skyrizi based on the knowledge base:

- Mechanism of Action: Skyrizi is a biologic therapy that targets IL-23, a protein involved in inflammation, helping to Show Full Answer

Switching to Skyrizi (risankizumab-rzaa) alone could be a viable option for managing your psoriatic arthritis (PsA) and psoriasis. Here are some key points about Skyrizi based on the knowledge base:

- Mechanism of Action: Skyrizi is a biologic therapy that targets IL-23, a protein involved in inflammation, helping to reduce joint pain, stiffness, and swelling.
- Administration: It is administered as a subcutaneous injection every 12 weeks after initial loading doses.
- Efficacy: Clinical trials (KEEPSAKE 1 and 2) showed significant improvement in PsA symptoms, with over half of participants experiencing reduced inflammation and swelling.
- Side Effects: Potential side effects include serious allergic reactions and an increased risk of infections.

Always discuss with your doctor to ensure this switch aligns with your specific health needs.

 This AI-generated response comes from MyPsoriasisTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

FDA Approves Skyrizi for Psoriatic Arthritis Following Promising Clinical Trials | MyPsoriasisTeam

Skyrizi (Risankizumab-rzaa) for Psoriasis | MyPsoriasisTeam